Form 4: Vertex CSO Sells Shares Under 10b5-1 Plan

Vertex Pharmaceuticals' EVP and Chief Scientific Officer, Mark E. Bunnage, reported the sale of common stock, including shares withheld for tax obligations, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark E. Bunnage, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving the company's common stock.
• On February 10, 2026, 1,127 shares of common stock were disposed of at a price of $468.41 per share to cover tax withholding obligations.
• On February 11, 2026, an additional 2,021 shares of common stock were sold at a price of $460.43 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan, which was established on November 26, 2025.
• Following these reported transactions, Mark E. Bunnage directly beneficially owns 12,914 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine for an executive managing equity compensation and were conducted under a pre-arranged 10b5-1 plan, including shares withheld for tax obligations.

Negatives

• Mark E. Bunnage, EVP, Chief Scientific Officer, sold 2,021 shares of common stock, reducing his direct beneficial ownership.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are a common practice for executives in the pharmaceutical industry and other sectors to manage personal finances, diversify holdings, and provide a defense against insider trading allegations by pre-scheduling transactions. This is a routine disclosure for a senior executive at a major pharmaceutical company.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, which is generally not considered significant given the routine nature of 10b5-1 plan transactions and tax-related dispositions.

Key Dates

Recommendation

The filing details routine insider stock transactions by an executive under a pre-arranged 10b5-1 plan, including shares disposed for tax purposes. This type of transaction is common and does not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.

Keywords

Vertex Pharmaceuticals, VRTX, insider trading, Form 4, stock sale, executive compensation, 10b5-1 plan, Mark E. Bunnage